BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies, today announced that it has been awarded the 2008 Frost & Sullivan Therapeutic Monoclonal Antibodies Technology Innovation of the Year Award for its Dynamic Cross Linking (DXL™) technology.
